Abstract
The mammalian target of rapamycin (mTOR) plays a critical role in the regulation of cell growth, proliferation, and metabolism by integrating growth factor stimulation and energy/nutrient input through a complex signaling network. The mTOR kinase is a part of two structurally and functionally distinct multiple protein complexes, mTORC1 and mTORC2. The mammalian target of rapamycin complex 1 (mTORC1) is rapamycin-sensitive and mediates temporal control of cell growth by regulating several cellular processes, such as translation, transcription, and nutrient transport while the mammalian target of rapamycin complex 2 (mTORC2) is insensitive to rapamycin and is involved in spatial control of cell growth via cytoskeleton regulation. Here we discuss the mechanism of mTOR regulation in tumor malignancy through a variety of signaling pathways and the potential of mTOR inhibitors for the treatment of cancer.
Keywords: AKT, cancer therapeutics, mTOR, PI3K
Current Cancer Drug Targets
Title:Targeting the mTOR Pathway in Tumor Malignancy
Volume: 13 Issue: 3
Author(s): Hengmiao Cheng, Marlena Walls, Sangita M. Baxi and Min-Jean Yin
Affiliation:
Keywords: AKT, cancer therapeutics, mTOR, PI3K
Abstract: The mammalian target of rapamycin (mTOR) plays a critical role in the regulation of cell growth, proliferation, and metabolism by integrating growth factor stimulation and energy/nutrient input through a complex signaling network. The mTOR kinase is a part of two structurally and functionally distinct multiple protein complexes, mTORC1 and mTORC2. The mammalian target of rapamycin complex 1 (mTORC1) is rapamycin-sensitive and mediates temporal control of cell growth by regulating several cellular processes, such as translation, transcription, and nutrient transport while the mammalian target of rapamycin complex 2 (mTORC2) is insensitive to rapamycin and is involved in spatial control of cell growth via cytoskeleton regulation. Here we discuss the mechanism of mTOR regulation in tumor malignancy through a variety of signaling pathways and the potential of mTOR inhibitors for the treatment of cancer.
Export Options
About this article
Cite this article as:
Cheng Hengmiao, Walls Marlena, M. Baxi Sangita and Yin Min-Jean, Targeting the mTOR Pathway in Tumor Malignancy, Current Cancer Drug Targets 2013; 13 (3) . https://dx.doi.org/10.2174/1568009611313030005
DOI https://dx.doi.org/10.2174/1568009611313030005 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Survey of Recent Literature Related to the Biologically Active 4(3H)-Quinazolinones Containing Fused Heterocycles
Current Medicinal Chemistry Alteration of Ceramide 1-O-Functionalization as a Promising Approach for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Retroviral Gene Therapy: Safety Issues and Possible Solutions
Current Gene Therapy Genomics and Proteomics of Nucleoside Transporters
Current Pharmacogenomics Analysis of Fish IL-1β and Derived Peptide Sequences Indicates Conserved Structures with Species-Specific IL-1 Receptor Binding: Implications for Pharmacological Design
Current Pharmaceutical Design Tyrosine Kinase Inhibitors
Current Cancer Drug Targets CD45 Regulated Signaling Pathways
Current Topics in Medicinal Chemistry Modulation of Antibiotic Efflux in Bacteria
Current Medicinal Chemistry - Anti-Infective Agents Liposomal-All-trans-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia
Current Cancer Therapy Reviews E2F1 and NF-κB: Key Mediators of Inflammation-associated Cancers and Potential Therapeutic Targets
Current Cancer Drug Targets Carbon Nanotubes: Classification, Method of Preparation and Pharmaceutical Application
Current Drug Delivery Major Challenges for Gene Therapy of Thalassemia and Sickle Cell Disease
Current Gene Therapy Mitochondrial DNA Mutations in Cancer: A Review
Current Topics in Medicinal Chemistry Pediatric Health Effects of Chronic Exposure to Extremely Low Frequency Electromagnetic Fields
Current Pediatric Reviews The Use of Cytokines and Chemokines in the Cancer Immunotherapy
Recent Patents on Anti-Cancer Drug Discovery Signal Transduction Pathways and Transcriptional Mechanisms as Targets for Prevention of Emergence of Multidrug Resistance in Human Cancer Cells
Current Drug Targets Novel Approaches to Modulate Apoptosis Resistance: Basic and Clinical Implications in the Treatment of Chronic Lymphocytic Leukemia (CLL)
Current Drug Delivery Mechanisms of Action of Imidazoacridinone and Triazoloacridinone Derivatives in View of their Biological Activity
Current Pharmaceutical Analysis (1→3)-α-D-Glucans from Aspergillus spp.: Structural Characterization and Biological Study on their Carboxymethylated Derivatives
Current Drug Targets The Management of Membranous Glomerulopathy in Allogeneic Stem Cells Transplantation: Updated Literature
Cardiovascular & Hematological Agents in Medicinal Chemistry